Clinical Trial · NCT06830408

Performance of 177Lu-PSMA-I&T for RLT in mCRPC - Prospective Multicenter Swiss Registry Study

Overview

The goal of this observational study (multicenter, national registry-based) is to evaluate the performance of 177Lu-ITG-PSMA-1 (177Lu-PSMA-I\&T) as therapy in patients with metastatic castration resistent prostate cancer (mCRPC). The main questions are whether the 177Lu-PSMA-I\&T is safe and if it works well to treat patients with progressive mCRPC. The data and information in the study are collected under standard medical therapy and follow-up, so called real-world conditions. Participants will: * undergo regular radioligand therapy (RLT) with 177Lu-PSMA-I\&T * have clinical, laboratory and imaging follow-up according to the currently available recommendation for PSMA-RLT an in line with their medical needs. * answer study related set of questionnaires

Sponsor

University Hospital, Basel, Switzerland

Contacts

Alin Chirindel (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT06830408

Drug / Compound

PSMA-I&T

Isotope(s):

Target(s):

PSMA

Ligand Class: Small Molecules

Chelator: DOTA

Eligibility

Inclusion

Inclusion criteria not yet provided.

Exclusion

patients withdrawing their consent for participation (NB: the already collected data in such cases will be anonymized and further used for applicable analyses)
patients who for medical or non-medical reasons are unable to give their consent
patients who are not eligible for PSMA RLT, according to current, standard medical indications and guidelines